

# Psychology of Addictive Behaviors

## **Types of Cannabis and Tobacco/Nicotine Co-Use and Associated Outcomes in Young Adulthood**

Joan S. Tucker, Eric R. Pedersen, Rachana Seelam, Michael S. Dunbar, Regina A. Shih, and Elizabeth J. D'Amico

Online First Publication, April 15, 2019. <http://dx.doi.org/10.1037/adb0000464>

### CITATION

Tucker, J. S., Pedersen, E. R., Seelam, R., Dunbar, M. S., Shih, R. A., & D'Amico, E. J. (2019, April 15). Types of Cannabis and Tobacco/Nicotine Co-Use and Associated Outcomes in Young Adulthood. *Psychology of Addictive Behaviors*. Advance online publication. <http://dx.doi.org/10.1037/adb0000464>

# Types of Cannabis and Tobacco/Nicotine Co-Use and Associated Outcomes in Young Adulthood

Joan S. Tucker, Eric R. Pedersen,  
and Rachana Seelam  
RAND Corporation, Santa Monica, California

Michael S. Dunbar  
RAND Corporation, Pittsburgh, Pennsylvania

Regina A. Shih  
RAND Corporation, Arlington, Virginia

Elizabeth J. D'Amico  
RAND Corporation, Santa Monica, California

Cannabis and tobacco/nicotine use are highly comorbid. Given expanding access to cannabis through legalization for recreational use, it is important to understand how patterns of cannabis and tobacco/nicotine co-use are associated with young adult outcomes. A predominantly California-based sample of 2,429 young adults (mean age = 20.7) completed an online survey. Based on past-year reports of cannabis and tobacco/nicotine use, we defined 5 mutually exclusive groups: (a) single-product use; (b) concurrent use only (using both products, but only on separate occasions); (c) sequential use only (using both products on the same occasion, one right after the other, but not mixing them together); (d) coadministration only (using both products on the same occasion by mixing them in the same delivery device); and (e) both sequential use and coadministration. We examined group differences in use patterns, dependence, consequences of use, and psychosocial functioning. Fifty percent of respondents reported cannabis use, 43% tobacco/nicotine use, and 37% co-use of both substances. The most prevalent method of co-use involved smoking combustible products. Overall, individuals who co-used both substances on the same occasion in some way reported heavier use and greater problematic behaviors than those who did not. Sequential use (especially among those that also engaged in coadministration) was typically associated with worse physical and mental functioning overall compared to using each substance separately. Findings illuminate both prevalence and risks associated with co-use of cannabis and tobacco/nicotine products and can inform policies for states considering regulation of cannabis and tobacco/nicotine products.

*Keywords:* marijuana, cannabis, tobacco, nicotine, co-use

In recent years, both cannabis and tobacco/nicotine products have become much more widely available to young adults. Stores that sell tobacco/nicotine products are ubiquitous. It is estimated that 375,000 U.S. retailers sell conventional tobacco products (e.g., combustible cigarettes), with 300,000 of these retailers also selling

electronic nicotine delivery systems (ENDS; Center for Public Health Systems Science, 2016). In addition, there has been a proliferation of both cannabis dispensaries and specialty vape shops (i.e., stores that sell only ENDS, but not other tobacco products) in states that have legalized cannabis for recreational sale and possession. For example, specialty vape shops in the United States listed on yelp.com increased from slightly less than 5,000 in 2002 to almost 10,000 in 2012 (Groskopf, 2016), and researchers have found that the number of vape shops near college campuses nearly tripled over a 2-year period from 2013 to 2015 (Dai & Hao, 2017). Given this increasing availability, it is perhaps not surprising that there has been an overall upward trend in recent years in the co-use of cannabis and tobacco/nicotine products among adults in the United States (Schauer, Berg, Kegler, Donovan, & Windle, 2015).

Prior to the proliferation of different types of cannabis and tobacco/nicotine products and methods of use, co-use of these products was generally limited to combustible methods. This could include smoking each type of product separately or after mixing them in some way. Studies indicate that use of one of these drugs increases the likelihood of using the other. For example, combus-

---

Joan S. Tucker, Eric R. Pedersen, and Rachana Seelam, RAND Corporation, Santa Monica, California; Michael S. Dunbar, RAND Corporation, Pittsburgh, Pennsylvania; Regina A. Shih, RAND Corporation, Arlington, Virginia; Elizabeth J. D'Amico, RAND Corporation, Santa Monica, California.

This research was supported by funds from Tobacco-Related Disease Research Program of the University of California. Grant 26IR-0011 to Joan S. Tucker, as well as grants from the National Institute of Alcohol Abuse and Alcoholism (R01AA016577, R01AA020883, R01AA025848) to Elizabeth J. D'Amico. We thank the districts and schools who participated and supported this project. We thank Kirsten Becker and Jennifer Parker for overseeing the data collection.

Correspondence concerning this article should be addressed to Joan S. Tucker, RAND Corporation, 1776 Main Street, Santa Monica, CA 90407. E-mail: jtucker@rand.org

tible tobacco use has been shown to lead to subsequent initiation of and increases in cannabis use (Agrawal, Budney, & Lynskey, 2012; Agrawal, Lynskey, Bucholz, Madden, & Heath, 2007; Lai, Lai, Page, & McCoy, 2000), and young adults who initiate cannabis use have been found to subsequently report more combustible tobacco use (Agrawal et al., 2012; Agrawal, Madden, Bucholz, Heath, & Lynskey, 2008; Behrendt, Wittchen, Höfler, Lieb, & Beesdo, 2009; Timberlake et al., 2007; Tullis, Dupont, Frost-Pineda, & Gold, 2003). Further, studies of young people have found that cannabis use can impede their efforts to quit cigarette smoking (Amos, Wiltshire, Bostock, Haw, & McNeill, 2004; Ramo, Delucchi, Hall, Liu, & Prochaska, 2013; Tullis et al., 2003).

In recent years, much attention has focused on the dramatic rise in the popularity of ENDS products (U.S. Department of Health & Human Services, 2016). ENDS are typically marketed as being used to vape e-liquids (which often contain nicotine) but can also be used to consume cannabis (Morean, Kong, Camenga, Cavallo, & Krishnan-Sarin, 2015; Prieur, 2018). Multiple studies indicate that over half of the people that report using ENDS also report using cannabis (Berg et al., 2015; Saddleson et al., 2015; U.S. Department of Health & Human Services, 2016). In a large nationally representative sample of 18- to 24-year-olds, those who used ENDS in the past 30 days were three times more likely to also report use of cannabis during that same period compared to young adults who did not use ENDS (Cohn et al., 2015). Further, available studies show that greater use of cannabis is related to greater use of ENDS to vape cannabis (Cranford, Bohnert, Perron, Bourque, & Ilgen, 2016; Frohe et al., 2017; Jones, Hill, Pardini, & Meier, 2016). The use of ENDS to vape cannabis (with or without nicotine) by young adults is also concerning because the short-term and long-term health consequences are largely unknown (Cranford et al., 2016; Giroud et al., 2015; Ramo, Liu, & Prochaska, 2012).

Although a research base on cannabis and tobacco/nicotine co-use is emerging, both in the United States and in other countries (Schauer, Rosenberry, & Peters, 2017), existing work on cannabis and tobacco/nicotine co-use has been limited in several key respects. First, most studies were conducted at a time when these substances were almost exclusively smoked and therefore do not reflect the recent proliferation in product types and methods of use (Russell, Rueda, Room, Tyndall, & Fischer, 2018). Understanding young adults' preferred methods of combining cannabis and tobacco/nicotine products is important because certain methods of co-use (e.g., combustible) may pose greater health risks than others (e.g., vaping). Second, studies have often assessed co-use in terms of whether the individual reported using both products during a specified period such as the past year or past month, ignoring whether these products were used together in some way—for example, using both products on the same occasion, one right after the other, but not mixing them together in the same delivery device (sequential use; e.g., smoking a joint and then smoking a cigarette), or mixing them in the same delivery device (coadministration; e.g., smoking a spliff that contains tobacco rolled in with cannabis). These distinctions have important implications for both the quantity consumed and the health effects of use, although research in this area is sparse and with methodological limitations (Meier & Hatsukami, 2016). For example, one study found that using products on the same occasion or mixing the products in the same delivery device are both associated with increased symptoms

of cannabis dependence (Ream, Benoit, Johnson, & Dunlap, 2008). In addition, coadministration, or mixing the products together, can significantly increase the amount of THC inhaled per gram of cannabis (Rabin & George, 2015). Further, individuals who use both cannabis and tobacco/nicotine are at elevated risk of poorer psychosocial functioning such as worse mental health, lower life satisfaction, more legal problems, and poor academic achievement in college (Georgiades & Boyle, 2007; Hernández-Serrano, Gras, & Font-Mayolas, 2018; Moore & Budney, 2001; Suris, Akre, Berchtold, Jeannin, & Michaud, 2007). However, it is important to better understand whether certain types of co-use (e.g., sequential co-use, coadministration) may elevate risk for poorer young adult outcomes.

## The Present Study

This study examined different types of co-use as a first step in understanding more detailed patterns of cannabis and tobacco/nicotine use among young adults, an age group that has the highest rates of both cannabis and tobacco/nicotine use (Azofeifa, 2016; Centers for Disease Control & Prevention, 2017; Hasin et al., 2015, 2016; Schauer et al., 2015; Substance Abuse and Mental Health Services Administration, 2017), as well as co-use of these products (Centers for Disease Control & Prevention, 2017; Schauer et al., 2015). We surveyed a diverse and predominantly California sample of 2,429 young adults in 2017–2018 about their use of cannabis and tobacco/nicotine products in the past year. We first describe the prevalence and most common methods of co-use (i.e., unique combinations of products). We categorized participants into one of five mutually exclusive groups: (a) single-product use (cannabis only; tobacco/nicotine only); (b) concurrent use only (using both products at some point, but only on separate occasions); (c) sequential use only (using both products on the same occasion, one right after the other, but not mixing them); (d) coadministration only (using both products by mixing them in the same delivery device); and (e) both sequential use and coadministration. These co-use groups were then compared on their frequency and heaviness of use, cannabis use disorder, cigarette and e-cigarette dependence, as well as indicators of psychosocial functioning. We hypothesized that young adults who engaged in any type of co-use (concurrent, sequential, or coadministration) would report worse functioning compared to those who reported cannabis-only or tobacco/nicotine-only use. Little research is available to help form hypotheses for specific co-use groups; however, we hypothesized that those who used cannabis and tobacco/nicotine products together in some way (i.e., sequential use, coadministration, or both) would report poorer outcomes than those who reported use of both substances but on separate occasions only (i.e., concurrent use only).

## Method

### Sample and Procedure

Participants originated from two cohorts of 6<sup>th</sup>- and 7<sup>th</sup>-grade students who were initially recruited in 2008 from 16 middle schools in southern California as part of a substance use prevention program, CHOICE (D'Amico et al., 2012). All students in the two cohorts who were followed to Wave 10 consented to the study

( $N = 6,509$ ), and all procedures were approved by the institution's review board. Participants completed Wave 1 (Fall, 2008) through Wave 5 (Spring, 2011) during physical education classes. Follow-up rates ranged from 74% to 90% during this time period, excluding new youth that could have come in at a subsequent wave. Adolescents transitioned from the 16 middle schools to over 200 high schools following Wave 5 and were subsequently recontacted and reconsented to complete annual web-based surveys, for which they were compensated. At Wave 6 (Spring 2013–Spring 2014), 61% of the sample participated in the follow-up survey. At the subsequent annual assessments, we retained 80% of the sample from Waves 6 to 7, 91% of the sample from Waves 7 to 8, 89% of the sample from Waves 8 to 9, and 90% of the sample from Waves 9 to 10. Demographics (e.g., gender, race/ethnicity, employment) and substance use at the prior wave (e.g., alcohol, cigarettes, marijuana) did not predict attrition at Wave 10, similar to what we have found at earlier waves (e.g., D'Amico et al., 2016).

The present analyses use Wave 10 data, which occurred between July 2017 and June 2018, which is the first wave we added items assessing different types of co-use. The full sample at Wave 10 consists of 2,429 respondents, with an average age of 20.67 years ( $SD = 0.70$ ). The sample is 45.62% male, 20.13% non-Hispanic White, 45.20% Hispanic, 20.75% Asian, 10.13% multiethnic, 2.31% Black, and 1.48% other races/ethnicities. The majority were still residing in California (93%) and were currently in college or trade school (80.28%). Within the full Wave 10 sample, 1,222 respondents reported past year cannabis use and 1,036 reported past year tobacco/nicotine use (as defined below). These two groups are the main focus of analyses, and their characteristics are presented in Table 1.

Table 1  
Sample Characteristics

| Characteristic                                 | Past year cannabis use group<br>( $n = 1,222$ ) |         | Past year tobacco/nicotine use group<br>( $n = 1,036$ ) |         |
|--|---|---------|---|---------|
|  | $n/M$   | %/ $SD$ | $n/M$   | %/ $SD$ |
| Demographics                                   |   |         |   |         |
| Age  | 20.65   | .69     | 20.68   | .71     |
| Race/ethnicity                                 |   |         |   |         |
| Hispanic                                       | 516   | 42.23%  | 444   | 42.86%  |
| Non-Hispanic                                   |   |         |   |         |
| White  | 319   | 26.10%  | 261   | 25.19%  |
| Asian  | 209   | 17.10%  | 185   | 17.86%  |
| Black  | 30  | 2.45%   | 18  | 1.74%   |
| Multiracial                                    | 134   | 10.97%  | 115   | 11.10%  |
| Other  | 14  | 1.15%   | 13  | 1.25%   |
| Male   | 577   | 47.22%  | 531   | 51.25%  |
| In college/trade school                        | 984   | 80.52%  | 819   | 79.05%  |
| Co-use status                                  |   |         |   |         |
| No co-use                                      | 344   | 28.15%  | 182   | 17.57%  |
| Concurrent use only                            | 374   | 30.61%  | 374   | 36.10%  |
| Coadministration use only <sup>a</sup>         | 122   | 9.98%   | 99  | 9.56%   |
| Sequential use only <sup>a</sup>               | 170   | 13.91%  | 173   | 16.70%  |
| Sequential + Coadministration use <sup>a</sup> | 212   | 17.35%  | 208   | 20.08%  |

<sup>a</sup> Differences in sample sizes across the cannabis use and tobacco/nicotine use samples for coadministration and sequential use are due to inconsistent reporting (e.g., endorsing a form of co-use, but not the individual cannabis and tobacco/nicotine items that comprise the co-use).

## Measures

**Past year cannabis and tobacco/nicotine use.** Separate items asked how often participants used each of eight cannabis products or devices in the past year: joint to smoke marijuana; blunt (cigar shell) that contains only marijuana (no tobacco); handpipe (bowl) to smoke marijuana; bong (waterpipe) to smoke marijuana; dabs (wax, shatter, budder, hash oil); edibles (e.g., brownies or candy); electronic cigarette or e-cigarette to smoke/vaporize marijuana; and personal vaporizer filled with hash oil, THC wax, dried buds, or other type of marijuana product. Separate items also asked how often participants had used each of the following seven tobacco/nicotine products or devices in the past year: cigarette, smokeless tobacco, hand pipe, hookah, large cigar/little cigar/cigarillo, e-cigarette (not for the purposes of using marijuana), and personal vaporizer filled with nicotine e-liquid or other type of tobacco product. Items were rated on a scale from 1 (*none*) to 6 (*more than 20 times*). These items were used to identify participants who had used a single type of product (cannabis or tobacco/nicotine) versus used both cannabis and tobacco/nicotine products in the past year.

**Past year cannabis and tobacco/nicotine co-use.** Participants who reported use of both cannabis and tobacco/nicotine rated how often in the past year they had “used both of these products/devices, one right after the other,” rated on a scale from 1 (*none*) to 6 (*more than 20 times*), as an indicator of sequential use. In addition, participants completed 10 items on how often they had “mixed tobacco and marijuana together” in different ways (cigarette dipped in hash oil; cigarette, joint, blunt, bong, hookah, hand pipe/bowl, or any other method that contained both tobacco and marijuana; e-cigarette or personal vaporizer that contained both nicotine e-liquid and marijuana), rated on a scale from 1 (*none*) to 6 (*more than 20 times*), as an indicator of coadministration. We then calculated the percent of participants who reported each type of sequential use and each type of coadministration. Given the strong correlation between e-cigarette and personal vaporizer use ( $r = .60$  for any use;  $r = .70$  for frequency), and potential for some participants to not differentiate between these terms for ENDS devices (Coleman, Johnson, Alexander, & Williams, 2018), we combined reported use of e-cigarettes or personal vaporizer into a single ENDS category. From this information we created five mutually exclusive groups based on reports of whether they had engaged in the following types of cannabis and tobacco/nicotine use in the past year (yes/no): (a) single-product use (cannabis only; tobacco/nicotine only); (b) concurrent use only (using both products, but only on separate occasions); (c) sequential use only (using both products at the same time, but not mixing them); (d) coadministration only (using both products by mixing them in the same delivery device); and (e) both sequential use and coadministration.

**Frequency of marijuana, cigarette, and e-cigarette use.** Measures of marijuana<sup>1</sup>, cigarette, and e-cigarette use were based on items from Monitoring the Future asking how often they had used or tried each of these products in the past year, rated on a scale from 1 (*none*) to 6 (*more than 20 times*). Response options were recoded to reflect the midpoint of number of times (e.g.,

<sup>1</sup> Note that survey items on frequency, quantity, and consequences/problems referred specifically to the use of marijuana, rather than using the cannabis term. As such, we use the term ‘marijuana’ when referring to these items in the Methods, Results, and tables.

11–20 times = 15.5) using an established approach (National Institute on Alcohol Abuse & Alcoholism, 2003; Osilla et al., 2014) to yield a continuous score ranging from 0 to 20 so model estimates could be interpreted as number of times a respondent used each substance/device in the past year.

**Quantity of marijuana, cigarette, and e-cigarette use.** For marijuana<sup>1</sup>, this was assessed by first asking how many times they used marijuana on the days they used and, for those who reported at least one time, asking, “On the days you use marijuana, on a typical use day, how much marijuana flower/bud do you personally consume (don’t include amount you may have shared)?” (Kilmer et al., 2013). Response options ranged from 1 (<0.25 grams) to 10 (more than 5 grams). Response options were recoded to reflect the mid-point number of grams to yield a continuous score ranging from 0.25 to 5.0 grams. Those who reported using marijuana zero times in the past year were coded as 0. To encourage accurate responses, we provided pictures of 0.5 gram, 1.0 gram, and 3.5 grams (eighth ounce) of marijuana flower/bud (Kilmer et al., 2013). We assessed quantity of cigarette and e-cigarette use, respectively, by asking, “On the days you smoke cigarettes, how many do you usually smoke” (response options were capped at 20 or more cigarettes per day) and “On the days that you use your e-cigarette, how many times per day do you usually use it? Assume that one “time” consists of around 15 puffs or lasts around 10 min” (response options were capped at 99 times). Those who reported smoking zero cigarettes in the past year or using e-cigarettes zero times were coded as 0 for these quantity items.

**Cannabis use disorder and cigarette/e-cigarette dependence.** We assessed symptoms of cannabis use disorder with the three-item Cannabis Use Disorder Identification Test Short-Form (CUDIT-SF; Bonn-Miller, Heinz, Smith, Bruno, & Adamson, 2016). Participants who reported past month marijuana use rated how often during the past 6 months they found that they were not able to stop using marijuana/cannabis once they had started; devoted a great deal of their time to getting, using, or recovering from marijuana/cannabis; and had problems with their memory or concentration after using marijuana/cannabis. Items were rated on a scale from 0 (never) to 4 (daily or almost daily) and then summed ( $\alpha = .70$ ; note that all reported alphas are based on full wave 10 sample). Among those reporting past month cigarette use, we used latency to first cigarette (“How soon after waking do you smoke your first cigarette?”) as an indicator of cigarette dependence (Baker et al., 2007). Similarly, for past month e-cigarette use, we used latency to first e-cigarette (“On days that you use your electronic cigarette freely, how soon after waking do you first use your electronic cigarette”) as an indicator of e-cigarette dependence (Foulds et al., 2015). Both items were rated on a 4-point scale, ranging from 1 (within 5 min) to 4 (after 60 min).

**Marijuana consequences and problems.** Negative consequences due to marijuana<sup>1</sup> use in the past year were assessed with a 10-item measure based on items from the RAND Adolescent/Young Adult Panel Study (Ellickson, D’Amico, Collins, & Klein, 2005) and the Marijuana Consequences Questionnaire (Simons, Dvorak, Merrill, & Read, 2012). Respondents were asked how many times various things had happened to them in the past year because of using marijuana (sample items: missed school, work, or other obligations; got into trouble; did something you later felt sorry for). Each item was rated from 1 (none) to 7 (20 or more times) and summed ( $\alpha = .91$ ). Using the same response scale, participants were also asked how often in the past year they

engaged in two marijuana<sup>1</sup> problematic behaviors: selling marijuana or driving a car after using marijuana.

**Delinquency.** Participants were asked about frequency of past year engagement in (nonsubstance use) delinquency, such as fighting, skipping school, getting fired from a job, and getting in trouble with the police. Items were modified from the RAND Adolescent/Young Adult Panel Study (Tucker, Orlando, & Ellickson, 2003) and were rated on a scale from 1 (none) to 6 (20 or more times) and summed ( $\alpha = .86$ ).

**Mental health.** Mental health was assessed with two measures. The eight-item Patient Health Questionnaire (PHQ-8; Kroenke et al., 2009) assessed eight symptoms of depression such as feeling down, depressed, or hopeless and having little interest or pleasure in doing things ( $\alpha = .92$ ). The Generalized Anxiety Disorder 7-item (GAD-7; Spitzer, Kroenke, Williams, & Löwe, 2006) assessed seven symptoms of anxiety such as feeling nervous, anxious, or on edge and not being able to stop or control worrying ( $\alpha = .94$ ). Both measures assessed symptoms in the past two weeks on a scale from 0 (not at all) to 3 (nearly every day).

**Physical health.** Physical ailments in the past four weeks were assessed with four items from the 15-item Patient Health Questionnaire (PHQ-15; Kroenke, Spitzer, & Williams, 2002) asking how much participants were bothered by stomach pain, headaches, feeling tired or having low energy, and trouble sleeping on a scale from 0 (not bothered at all) to 2 (bothered a lot). Each item was dichotomized as 0 (not bothered at all) vs. 1 (bothered a little/bothered a lot), and the four items were summed to create an overall physical ailment score ( $\alpha = .75$ ). Physical health was assessed with a combination of subjective overall health, ranging from 1 (excellent) to 5 (poor), and two items from the Patient-Reported Outcomes Measurement Information System (PROMIS; DeWitt, Stucky, Thissen, Irwin, & Langer, 2011) for ability to physically engage in activities that one enjoys and ability to participate in sports/activities similar to their peers ranging from 1 (with no trouble) to 5 (not able to do). Items were reverse scored and summed, with higher scores indicating better physical health ( $\alpha = .80$ ).

**Social functioning.** Lastly, social functioning was assessed with eight PROMIS peer relationship items (DeWalt et al., 2013) rated from 0 (never) to 4 (always). Items included “I was able to count on my friends,” “I felt accepted by other people my age,” and “I was good at making friends” ( $\alpha = .96$ ).

**Sociodemographics and race/ethnicity.** Variables included age, gender, current attendance in college/trade school, and race/ethnicity. Participants were classified into one of six racial/ethnic groups: Hispanic and five non-Hispanic groups—White (reference group), Black, Asian, Multiracial (more than one race), and Other (e.g., Native American, Native Hawaiian).

## Analytic Approach

Analyses describing the prevalence of different types of sequential use (see Table 2) and coadministration (see Table 3) within the full sample, and among those who reported using both cannabis and tobacco/nicotine in the past year, were primarily descriptive. A secondary analysis explored differences by gender and race/ethnicity, within the full sample, in any sequential use (yes/no) and any coadministration (yes/no). Analysis of covariance tests and follow-up Tukey post hoc tests were conducted to compare the five

Table 2  
*Past Year Sequential Co-Use of Cannabis and Tobacco/Nicotine in Full Sample and Among Past Year Cannabis and Tobacco/Nicotine Co-Use Groups (Combinations With  $\geq 10\%$  Prevalence Among Co-Use Sample Are Shown)*

| Type of sequential co-use  | % among full sample | % among co-use sample |
|--|---------------------|-----------------------|
| Any type of sequential co-use ( $n = 401$ )  | 16.51%              | 44.41%                |
| Cigarette + Joint to smoke marijuana ( $n = 179$ )                                 | 7.41%               | 19.93%                |
| ENDS <sup>a</sup> + Joint to smoke marijuana ( $n = 157$ )                         | 6.46%               | 17.39%                |
| ENDS <sup>a</sup> + E-cigarette/vaporizer to use marijuana ( $n = 157$ )           | 6.46%               | 17.39%                |
| Cigarette + Blunt (cigar shell) that contains only marijuana ( $n = 150$ )         | 6.21%               | 16.76%                |
| ENDS <sup>a</sup> + Bong (waterpipe) to smoke marijuana ( $n = 148$ )              | 6.09%               | 16.39%                |
| Cigarette + Bong (waterpipe) to smoke marijuana ( $n = 141$ )                      | 5.84%               | 15.75%                |
| ENDS <sup>a</sup> + Blunt (cigar shell) that contains only marijuana ( $n = 135$ ) | 5.56%               | 14.95%                |
| ENDS <sup>a</sup> + Hand pipe (bowl) to smoke marijuana ( $n = 122$ )              | 5.02%               | 13.51%                |
| Cigarette + Hand pipe (bowl) to smoke marijuana ( $n = 117$ )                      | 4.84%               | 13.01%                |
| Cigarette + E-cigarette/vaporizer to use marijuana ( $n = 111$ )                   | 4.57%               | 12.29%                |
| ENDS <sup>a</sup> + Dabs (wax, shatter, budder, hash oil; $n = 104$ )              | 4.28%               | 11.52%                |
| ENDS <sup>a</sup> + Edible (e.g., brownies or candy; $n = 102$ )                   | 4.20%               | 11.30%                |

Note. ENDS = electronic nicotine delivery systems.  $N = 2,429$  for full sample and  $n = 903$  for co-use sample. Tobacco/nicotine product is listed first, followed by cannabis product.

<sup>a</sup> Indicates endorsement of the item on using e-cigarettes (not for the purpose of using marijuana) and/or the item on use of personal vaporizer filled with nicotine e-liquid or other type of tobacco/nicotine product.

mutually exclusive groups: single substance use; concurrent use only (no sequential use or coadministration); coadministration only (no sequential use); sequential use only (no coadministration); and those who reported both sequential use and coadministration. Separate analyses were conducted to compare the cannabis-only use group to each co-use group (see Table 4), and to compare the tobacco/nicotine-only use group to each co-use group (see Table 5). These group comparisons controlled for sociodemographic covariates described above.

## Results

### Prevalence and Methods of Cannabis and Tobacco/Nicotine Co-Use

In the full sample ( $N = 2,429$ ), 50.31% ( $n = 1,222$ ) of respondents reported past year use of any cannabis product, 42.65% ( $n =$

1,036) reported past year use of any tobacco/nicotine product, and 37.18% ( $n = 903$ ) reported past year use of both cannabis and tobacco/nicotine products. Sequential use of cannabis and tobacco/nicotine (using both products at the same time, one right after another, but not mixing them) was reported by 401 respondents, which was 16.51% of the full sample and 44.41% of those who used both products in the past year. Coadministration of cannabis and tobacco/nicotine (using both at the same time by mixing them in the same delivery device) was reported by 342 respondents, which was 14.08% of the full sample and 35.87% of those who used both products in the past year.

Secondary analyses exploring racial/ethnic differences found an overall difference in both sequential use,  $F(5, 2423) = 3.45$ ,  $p = .004$ , and coadministration,  $F(5, 2423) = 15.13$ ,  $p < .001$ , within the full sample. Tukey post hoc comparisons found that sequential use was more common among non-Hispanic Whites than Hispan-

Table 3  
*Past Year Coadministration of Cannabis and Tobacco/Nicotine in Full Sample and Among Past Year Cannabis and Tobacco/Nicotine Co-Use Groups*

| Type of coadministration   | % among full sample | % among co-use sample |
|--|---------------------|-----------------------|
| Any type of coadministration ( $n = 342$ )   | 14.08%              | 35.87%                |
| Joint that contains both tobacco and marijuana ( $n = 243$ )   | 10.03%              | 27.00%                |
| Bong that contains both tobacco and marijuana ( $n = 191$ )  | 7.89%               | 21.27%                |
| Blunt that contains both tobacco and marijuana ( $n = 188$ )   | 7.76%               | 20.89%                |
| Cigarette that contains both tobacco and marijuana ( $n = 104$ )   | 4.29%               | 11.56%                |
| Hand pipe or bowl that contains both tobacco and marijuana ( $n = 92$ )                                    | 3.80%               | 10.22%                |
| ENDS that contains both nicotine e-liquid and marijuana (such as hash oil, THC wax, dried buds; $n = 79$ ) | 3.25%               | 8.75%                 |
| Any other way of using both tobacco and marijuana through the same delivery device ( $n = 58$ )            | 2.40%               | 6.45%                 |
| Hookah that contains both tobacco and marijuana ( $n = 49$ )   | 2.02%               | 5.44%                 |
| Cigarette dipped in hash oil ( $n = 48$ )  | 1.98%               | 5.33%                 |

Note. ENDS = electronic nicotine delivery systems.  $N = 2,429$  for full sample and  $n = 903$  for co-use sample.

Table 4  
Comparing Cannabis Only Use Group to Concurrent Use, Sequential Use, and Coadministration Use Groups

| Variable                   | Group 1:<br>Cannabis<br>use only | Group 2:<br>Concurrent<br>use only | Group 3:<br>Co-admin.<br>only | Group 4:<br>Sequential<br>use only | Group 5:<br>Sequential + co-<br>administration | Overall<br>ANCOVA  | Group differences <sup>a</sup>         |
|----------------------------|----------------------------------|------------------------------------|-------------------------------|------------------------------------|--|--------------------|--|
|                            | <i>M (SE)</i>                    | <i>M (SE)</i>                      | <i>M (SE)</i>                 | <i>M (SE)</i>                      | <i>M (SE)</i>                                  | <i>F (df = 8)</i>  |  |
| Frequency of marijuana use | 8.55 (.40)                       | 9.94 (.38)                         | 15.05 (.67)                   | 12.60 (.57)                        | 17.30 (.51)                                    | 32.82 <sup>‡</sup> | 1/3, 2/3, 1/4, 2/4, 3/4, 1/5, 2/5, 4/5 |
| Quantity of marijuana use  | .58 (.05)                        | .53 (.05)                          | .90 (.08)                     | .94 (.07)                          | 1.04 (.06)                                     | 17.67 <sup>‡</sup> | 1/3, 2/3, 1/4, 2/4, 1/5, 2/5           |
| CUD <sup>b</sup>           | 1.02 (.19)                       | 1.21 (.17)                         | 1.83 (.26)                    | 1.54 (.22)                         | 2.81 (.18)                                     | 12.15 <sup>‡</sup> | 1/5, 2/5, 3/5, 4/5                     |
| Marijuana consequences     | 13.11 (.46)                      | 14.12 (.44)                        | 18.30 (.77)                   | 16.64 (.65)                        | 22.29 (.59)                                    | 28.32 <sup>‡</sup> | 1/3, 2/3, 1/4, 2/4 1/5, 2/5, 3/5, 4/5  |
| Marijuana selling          | .04 (.02)                        | .05 (.02)                          | .15 (.03)                     | .16 (.02)                          | .23 (.02)                                      | 14.76 <sup>‡</sup> | 1/3, 2/3, 1/4, 2/4 1/5, 2/5            |
| Marijuana-impaired driving | .15 (.02)                        | .21 (.02)                          | .47 (.04)                     | .38 (.03)                          | .55 (.03)                                      | 21.62 <sup>‡</sup> | 1/3, 2/3, 1/4, 2/4, 1/5, 2/5, 4/5      |
| Delinquency                | 6.41 (.15)                       | 6.56 (.14)                         | 6.67 (.25)                    | 7.13 (.21)                         | 8.53 (.19)                                     | 15.68 <sup>‡</sup> | 1/4, 1/5, 2/5, 3/5, 4/5                |
| Physical ailments          | 2.09 (.07)                       | 1.92 (.07)                         | 2.21 (.12)                    | 2.13 (.11)                         | 2.40 (.10)                                     | 6.94 <sup>‡</sup>  | 2/5                                    |
| Physical health            | 12.21 (.13)                      | 12.43 (.12)                        | 12.29 (.21)                   | 11.68 (.18)                        | 11.76 (.16)                                    | 6.34 <sup>‡</sup>  | 2/4, 2/5                               |
| Social functioning         | 42.66 (.41)                      | 43.18 (.39)                        | 43.99 (.69)                   | 42.41 (.58)                        | 43.17 (.52)                                    | 3.97 <sup>‡</sup>  | —                                      |
| Anxiety                    | 5.73 (.29)                       | 4.74 (.28)                         | 5.31 (.50)                    | 5.88 (.42)                         | 6.67 (.38)                                     | 4.44 <sup>‡</sup>  | 2/5                                    |
| Depression                 | 5.71 (.31)                       | 5.42 (.29)                         | 5.83 (.51)                    | 6.90 (.43)                         | 7.57 (.39)                                     | 5.79 <sup>‡</sup>  | 1/5, 2/4, 2/5                          |
| <i>n</i>                   | 344                              | 374                                | 122                           | 170                                | 212  |                    |  |

Note. CUD = cannabis use disorder; ANCOVA = analysis of covariance. Adjusted means and SEs after controlling for age, gender, race/ethnicity, and college status are shown.

<sup>a</sup> Group differences significant at  $p < .05$  from pairwise comparisons. <sup>b</sup> Past month marijuana use only ( $n = 738$ ).

<sup>‡</sup>  $p < .001$ .

ics (21.88% vs. 14.12%,  $p < .05$ ). Coadministration was more likely among non-Hispanic Whites (24.74%) than Hispanics (9.93%), Asians (10.71%), and those in the Other group (5.56%), and more prevalent in the Multiethnic group than among Hispanics (18.29% vs. 9.93%) ( $ps < .05$ ). In addition, males were more likely than females to engage in both sequential use (22.20% vs.

11.73%;  $t = 6.84$ ,  $p < .0001$ ) and coadministration (18.68% vs. 10.22%;  $t = 5.89$ ,  $p < .0001$ ).

As shown in Table 2, the most prevalent forms of sequential use, or using one product right after the other, were cigarette and joint (7.41% of full sample), ENDS and joint (6.46%), ENDS and e-cigarette/vaporizer for marijuana (6.46%), cigarette and blunt

Table 5  
Comparing Tobacco/Nicotine Only Use Group to Concurrent Use, Sequential Use, and Coadministration Use Groups

| Variable                               | Group 1:<br>Tobacco<br>use only | Group 2:<br>Concurrent<br>use only | Group 3:<br>Co-admin.<br>only | Group 4:<br>Sequential<br>use only | Group 5:<br>Sequential + co-<br>administration | Overall<br>ANCOVA  | Group differences <sup>a</sup>         |
|--|---------------------------------|------------------------------------|-------------------------------|------------------------------------|--|--------------------|--|
|  | <i>M (SE)</i>                   | <i>M (SE)</i>                      | <i>M (SE)</i>                 | <i>M (SE)</i>                      | <i>M (SE)</i>                                  | <i>F (df = 8)</i>  |  |
| Frequency of cigarette use             | 3.58 (.51)                      | 3.74 (.36)                         | 6.97 (.70)                    | 5.77 (.52)                         | 11.01 (.48)                                    | 27.36 <sup>‡</sup> | 1/3, 2/3, 1/4, 2/4, 1/5, 2/5, 3/5, 4/5 |
| Frequency of e-cigarette use           | 2.66 (.53)                      | 3.36 (.37)                         | 5.33 (.72)                    | 5.76 (.54)                         | 9.51 (.49)                                     | 23.67 <sup>‡</sup> | 1/3, 1/4, 2/4, 1/5, 2/5, 3/5, 4/5      |
| Quantity of cigarette use              | .50 (.17)                       | .39 (.12)                          | 1.02 (.23)                    | .96 (.17)                          | 1.71 (.16)                                     | 9.00 <sup>‡</sup>  | 2/4, 1/5, 2/5, 4/5                     |
| Quantity of e-cigarette use            | 1.66 (.91)                      | 1.97 (.65)                         | 3.20 (1.27)                   | 5.86 (.94)                         | 7.24 (.86)                                     | 5.58 <sup>‡</sup>  | 1/4, 2/4, 1/5, 2/5                     |
| Time to first cigarette <sup>b</sup>   | 3.79 (.12)                      | 3.62 (.09)                         | 3.57 (.14)                    | 3.47 (.10)                         | 3.69 (.07)                                     | 2.14*              | —                                      |
| Time to first e-cigarette <sup>c</sup> | 3.47 (.12)                      | 3.39 (.07)                         | 3.31 (.13)                    | 3.22 (.09)                         | 3.31 (.08)                                     | 1.98*              | —                                      |
| Delinquency                            | 6.31 (.22)                      | 6.59 (.15)                         | 6.70 (.30)                    | 7.22 (.22)                         | 8.58 (.20)                                     | 12.65 <sup>‡</sup> | 1/4, 1/5, 2/5, 3/5, 4/5                |
| Physical ailments                      | 2.05 (.10)                      | 1.89 (.07)                         | 2.15 (.14)                    | 2.14 (.10)                         | 2.40 (.10)                                     | 8.79 <sup>‡</sup>  | 2/5                                    |
| Physical health                        | 12.54 (.17)                     | 12.43 (.12)                        | 12.30 (.24)                   | 11.70 (.18)                        | 11.76 (.16)                                    | 6.61 <sup>‡</sup>  | 1/4, 2/4, 1/5, 2/5                     |
| Social functioning                     | 42.67 (.56)                     | 43.22 (.44)                        | 43.87 (.76)                   | 42.49 (.57)                        | 43.07 (.53)                                    | 3.70 <sup>‡</sup>  | —                                      |
| Anxiety                                | 6.00 (.41)                      | 4.69 (.29)                         | 5.19 (.56)                    | 5.77 (.42)                         | 6.66 (.38)                                     | 4.80 <sup>‡</sup>  | 2/5                                    |
| Depression                             | 6.16 (.43)                      | 5.41 (.30)                         | 5.95 (.58)                    | 6.77 (.44)                         | 7.58 (.40)                                     | 5.74 <sup>‡</sup>  | 2/5                                    |
| <i>n</i>                               | 182                             | 374                                | 99                            | 173                                | 208  |                    |  |

Note. ANCOVA = analysis of covariance. Adjusted means and SEs after controlling for age, gender, race/ethnicity, and college status are shown.

<sup>a</sup> Group differences significant at  $p < .05$  from pairwise comparisons. <sup>b</sup> Past month cigarette use only ( $n = 375$ ). <sup>c</sup> Past month e-cigarette use only ( $n = 1,015$ ).

<sup>‡</sup>  $p < .001$ . \*  $p < .05$ .

(6.21%), ENDS and bong (6.09%), cigarette and bong (5.84%), ENDS and blunt (5.56%), and ENDS and hand pipe (5.02%). All other combinations were mentioned by less than 5% of the full sample. Table 3 contains the 10 forms of coadministration listed in order of prevalence. The most common forms of coadministration, or mixing of products, were joints (10.03% of the total sample), bongs (7.89%), and blunts (7.76%) that contained both marijuana and tobacco. All other forms of coadministration were mentioned by less than 5% of the full sample.

### Comparing Cannabis-Only Group to the Four Co-Use Groups

Table 4 contains means and standard errors for each outcome by subgroup, as well as the overall analysis of covariance test statistic and significant findings between subgroups.

**Marijuana use and cannabis use disorder.** As hypothesized, we found overall group differences on marijuana use and CUDIT-SF score based on the use group. The three co-use groups that used cannabis and tobacco/nicotine products on the same occasion in some way (coadministration, sequential, or both) reported more days of marijuana use than the cannabis-only group; however, there was not a significant difference in heaviness of use between the group that had used both products in the past year, but never on the same occasion (concurrent only), and the cannabis-only group. Further, the two groups that reported coadministration of products reported more frequent marijuana use than the sequential-only and concurrent-only groups, and the sequential-only group reported more frequent marijuana use than the concurrent-only group.

In terms of marijuana quantity, the three co-use groups that used both products on the same occasion reported consuming more grams of marijuana on a typical day of use compared to either the cannabis-only group or the concurrent-only group. For example, the sequential + coadministration group reported using about a gram of marijuana when they used, which is a little larger than a bottle cap, compared to about ½ a gram for the cannabis-only and concurrent-only groups. On the CUDIT-SF, the sequential + coadministration group reported a mean CUDIT-SF score that was higher than the cutoff score of 2, which is indicative of cannabis use disorder; the score for this group was significantly higher than for any of the other four groups.

**Marijuana problems.** A comparison of the five mutually exclusive cannabis groups found overall differences on each outcome. For marijuana-related consequences, the three co-use groups that used cannabis and tobacco/nicotine products on the same occasion reported greater consequences than the cannabis-only group; however, there was not a significant difference in consequences between the group that had used both products in the past year, but never on the same occasion (concurrent use only), and the cannabis-only group. The sequential + coadministration group reported more consequences than the sequential-only, coadministration-only, and concurrent-only groups. In turn, the sequential-only and coadministration-only groups reported more consequences than the concurrent-only group. For selling marijuana, the three co-use groups that used both products on the same occasion were more likely to sell the drug compared to the cannabis-only group and the concurrent-only group. Considering the means, about 20% of those in the sequential + coadministration group reported selling marijuana compared to only 4% in the

cannabis-only group and 10% in the concurrent-only group. Lastly, for driving after marijuana use, the three co-use groups that used both products on the same occasion were more likely to drive after using marijuana compared to the cannabis-only group and the concurrent-only group. The sequential + coadministration group was also more likely to drive after using marijuana than the sequential-only group. Compared to 15% of the cannabis-only use group, 47% of the coadministration-only group and 55% of the sequential + coadministration group reported driving after use.

**Delinquency, physical health, mental health, and social functioning.** We found overall group differences on delinquency, physical ailments, physical health, anxiety, and depression. For delinquency, those in the sequential + coadministration group reported greater past year delinquency compared to all other groups. In addition, the sequential-only group reported greater delinquency than the cannabis-only group. Regarding physical ailments and health, the sample overall reported good physical health; however, the sequential + coadministration group reported more physical ailments and poorer health than the concurrent-only group and the sequential-only group reported poorer health than the concurrent-only group. For anxiety, those in the sequential + coadministration group reported greater anxiety symptoms than the concurrent-only group. For depression, those in the sequential + coadministration group reported greater depression symptoms than the cannabis-only and concurrent-only groups, and the sequential-only group reported greater depression symptoms than the concurrent-only group. Means across the groups were generally mild to moderate, as scores of 10 on the GAD-7 and the PHQ-8 indicate positive screens for anxiety and depression, respectively. There were no significant differences between groups for social functioning.

### Comparing the Tobacco/Nicotine-Only Group and the Four Co-Use Groups

Table 5 contains means and standard deviations for each outcome by co-use subgroup, as well as the overall analysis of covariance test statistic and significant subgroup differences.

**Tobacco/nicotine use and dependence.** A comparison of the five mutually exclusive tobacco/nicotine groups found overall group differences on tobacco/nicotine use and dependence. The sequential + coadministration group reported significantly more frequent cigarette use and e-cigarette use in the past year compared to the tobacco/nicotine-only group and the other three co-use groups. In addition, the sequential-only group reported more frequent cigarette use and e-cigarette use than the concurrent-only and tobacco/nicotine-only groups. Finally, the coadministration-only group reported more frequent cigarette and e-cigarette use than the tobacco/nicotine-only group, and more frequent cigarette use compared to the concurrent-only group. In terms of quantity of use, the sequential + coadministration group reported higher quantity of both cigarette and e-cigarette use compared to the tobacco/nicotine-only group and concurrent-only group, and higher quantity of cigarette use compared to the sequential-only group. In addition, the sequential-only group reported a higher quantity of both cigarette and e-cigarette use compared to the concurrent-only group, and a higher quantity of e-cigarette use compared to the tobacco/nicotine-only group. Even though there was an overall effect between groups, post hoc tests revealed there were no mean



differences between groups on the indicators of cigarette or e-cigarette dependence.

**Delinquency, physical health, mental health, and social functioning.** Similar to comparisons for the cannabis-only use group, we found overall group differences on delinquency, physical ailments, physical health, anxiety and depression. For delinquency, those in the sequential + coadministration group reported greater past year delinquency than all other groups. The sequential-only group also reported greater delinquency than the tobacco/nicotine-only group. For physical ailments, the sequential + coadministration group reported more physical ailments than the concurrent-only group. Regarding physical health, the sequential + coadministration group and the sequential-only group reported poorer health than the tobacco/nicotine-only group and the concurrent-only group. For both anxiety and depression, the sequential + coadministration group reported greater symptoms than the concurrent-only group. There were no significant differences between groups for social functioning.

## Discussion

Studies have shown that cannabis and tobacco/nicotine use are highly comorbid in young adulthood (Schauer et al., 2015); however, little research has provided detailed information on how these substances are used together. This study is among the first to examine unique combinations of cannabis and tobacco/nicotine use and different types of co-use behaviors in a diverse sample of young adults. We found that the most popular forms of both sequential use (using one product right after another) and coadministration (mixing the products) involved smoking combustible products (i.e., cigarettes, joints, bongos, blunts). Vaping methods for co-use of cannabis and tobacco/nicotine were somewhat less prevalent, as noted in prior work (Meier & Hatsukami, 2016), but may grow in popularity over time given the recent alarming increase in vaping among high school students (Cullen et al., 2018). Combustible cigarette use has declined substantially over the past 50 years (Lauterstein et al., 2014; National Center for Chronic Disease Prevention and Health Promotion Office on Smoking & Health, 2014). However, our study shows that despite these declining rates, the highest rates of cannabis and tobacco/nicotine co-use are through combustible methods. Though the long-term health effects of vaping nicotine (with or without cannabis) are still being actively studied without firm conclusions (Budney, Sargent, & Lee, 2015; Giroud et al., 2015; Pisinger & Døssing, 2014), vaping is almost certainly a less harmful variant of substance use than smoking combustible products (National Academies of Sciences & Medicine, 2018). Findings emphasize the continued need for early education programs to address the dangers of smoking combustible products, and interventions for those that have already begun smoking to prevent adverse health effects.

Mixing cannabis and tobacco is prevalent in several countries but has generally been considered to be rare in the United States (Winstock, Barratt, Ferris, & Maier, 2017). Thus, another interesting finding from this study is that the majority of young adults who co-use cannabis and tobacco/nicotine products use them together in some way. Among those who reported using both cannabis and tobacco/nicotine products in the past year, nearly one half had used the two products one after the other on the same occasion (sequential use) and about one third mixed them in the same delivery

device (coadministration). The heterogeneity within the population is important to consider, as some co-use subgroups had higher risk profiles than others. For example, young adults who co-used cannabis and tobacco/nicotine on the same occasion, or mixed the products in the same device, tended to report higher frequency and quantity of marijuana or tobacco/nicotine use compared to those who used only one product. Of note, we did not see these same increases among young adults who used cannabis and tobacco/nicotine on separate occasions only. We did not find that cigarette or e-cigarette dependence was higher among any of the co-use subgroups compared to the tobacco/nicotine-only group; however, consistent with other work (Peters, Budney, & Carroll, 2012), cannabis use disorder scores were significantly higher in the sequential + coadministration group compared to the cannabis-only group. We found a similar pattern for marijuana consequences, marijuana problems (selling the drug, driving after using it), and most domains of young adult functioning. Overall, youth who reported coadministration and sequential use, either alone or in combination, also reported poorer outcomes compared to youth using only one product or using both products independently. There is some literature on psychosocial and physical health correlates of co-use in young adults (Masters, Haardörfer, Windle, & Berg, 2018; Ramo et al., 2012); however, further longitudinal research is needed to examine how outcomes may differ across types of co-use over time and to identify mechanisms underlying these differences. For example, differences across types of co-use may be due to the manner in which cannabis and tobacco/nicotine are co-used, characteristics of the person who chooses to co-use in a particular way, or other factors. Additional research on co-use is also needed to inform various stakeholder groups, including policymakers and public health officials, and to guide both tobacco and cannabis regulatory science (Schlienz & Lee, 2018).

It is clear from this study and others (Agrawal et al., 2012; Meier & Hatsukami, 2016; Ramo et al., 2012) that any research study assessing the effects of cannabis or tobacco/nicotine use (e.g., whether use contributes to poor physical and mental health) should also account for co-use of these products given the prevalence of this behavior among young adults. Given the changing legal landscape of cannabis (D'Amico, Tucker, Pedersen, & Shih, 2017), and the fact that co-use is associated with more frequent and problematic use, poorer mental and physical health, and delinquent behaviors such as getting fired from a job or getting in trouble with the police, it will be important for programming to include content and discussions geared toward co-use of both products, and how co-use may also lead to problems.

## Limitations

Data were collected in a state where medical cannabis had been legal for about 20 years, mostly (but not exclusively) prior to the retail sale of recreational cannabis going into effect in January 2018. The use of this predominantly California-based sample limits generalizability of findings; however, the use of such a sample allowed us to have a diverse sample of young adults (74% of youth who reported cannabis use were non-White) and offered some standardization of both cannabis and tobacco state policies applied to all participants in the study. Though this study represents the most detailed effort to collect information on specific types of co-use products, our online survey methods relied on

self-report data from one time-point. With the recent opening of recreational dispensaries in California and other states, the proliferation of specialty vape shops, and the ubiquitous availability of tobacco/nicotine products, it is essential to create well-designed longitudinal studies that can address important policy questions, such as whether legalizing cannabis for recreational sale and possession has an unintended impact on increasing tobacco use among young adults. We also were not able to assess the relative quantity of cannabis versus tobacco/nicotine within the coadministration device. This study was meant to provide an overview of the extent of co-use among young adults. There is a need for more detailed data on recent and regular use (e.g., past week), and specifically at the daily level, perhaps using ecological momentary assessment to disentangle order of product use and better understand quantities of use for both drugs.

### Conclusions

This study represents an important first step toward understanding cannabis and tobacco/nicotine co-use behavior among young adults. We detailed the most popular forms of sequential use and coadministration, finding that young adults who engage in certain types of co-use are at high risk for more frequent use of both drugs, more frequent consequences, and poorer psychosocial functioning than other co-use groups and single product use groups. Longitudinal research and data collection methods are needed that gather more nuanced details, such as the order of product use on sequential occasions and predictors of coadministration and sequential use which were the highest risk groups for negative consequences. Overall, these descriptive findings emphasize the need for prevention and intervention efforts to target both cannabis and tobacco/nicotine use (including sequential use and coadministration) in the effort to address long-term health problems and problematic behaviors related to both drugs.

### References

- Agrawal, A., Budney, A. J., & Lynskey, M. T. (2012). The co-occurring use and misuse of cannabis and tobacco: A review. *Addiction, 107*, 1221–1233. <http://dx.doi.org/10.1111/j.1360-0443.2012.03837.x>
- Agrawal, A., Lynskey, M. T., Bucholz, K. K., Madden, P. A., & Heath, A. C. (2007). Correlates of cannabis initiation in a longitudinal sample of young women: The importance of peer influences. *Preventive Medicine: An International Journal Devoted to Practice and Theory, 45*, 31–34. <http://dx.doi.org/10.1016/j.ypmed.2007.04.012>
- Agrawal, A., Madden, P. A., Bucholz, K. K., Heath, A. C., & Lynskey, M. T. (2008). Transitions to regular smoking and to nicotine dependence in women using cannabis. *Drug and Alcohol Dependence, 95*, 107–114. <http://dx.doi.org/10.1016/j.drugalcdep.2007.12.017>
- Amos, A., Wiltshire, S., Bostock, Y., Haw, S., & McNeill, A. (2004). ‘You can’t go without a fag . . . you need it for your hash’—A qualitative exploration of smoking, cannabis and young people. *Addiction, 99*, 77–81. <http://dx.doi.org/10.1111/j.1360-0443.2004.00531.x>
- Azofeifa, A. (2016). National estimates of marijuana use and related indicators—National Survey on Drug Use and Health, United States, 2002–2014. *MMWR: Surveillance Summaries, 65*, 1–28. <http://dx.doi.org/10.15585/mmwr.ss6511a1>
- Baker, T. B., Piper, M. E., McCarthy, D. E., Bolt, D. M., Smith, S. S., Kim, S. Y., . . . Toll, B. A. (2007). Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. *Nicotine & Tobacco Research, 9*(Suppl. 4), S555–S570.
- Behrendt, S., Wittchen, H.-U., Höfler, M., Lieb, R., & Beesdo, K. (2009). Transitions from first substance use to substance use disorders in adolescence: Is early onset associated with a rapid escalation? *Drug and Alcohol Dependence, 99*, 68–78. <http://dx.doi.org/10.1016/j.drugalcdep.2008.06.014>
- Berg, C. J., Stratton, E., Schauer, G. L., Lewis, M., Wang, Y., Windle, M., & Kegler, M. (2015). Perceived harm, addictiveness, and social acceptability of tobacco products and marijuana among young adults: Marijuana, hookah, and electronic cigarettes win. *Substance Use & Misuse, 50*, 79–89. <http://dx.doi.org/10.3109/10826084.2014.958857>
- Bonn-Miller, M. O., Heinz, A. J., Smith, E. V., Bruno, R., & Adamson, S. (2016). Preliminary development of a brief cannabis use disorder screening tool: The Cannabis Use Disorder Identification Test Short-Form. *Cannabis and Cannabinoid Research, 1*, 252–261. <http://dx.doi.org/10.1089/can.2016.0022>
- Budney, A. J., Sargent, J. D., & Lee, D. C. (2015). Vaping cannabis (marijuana): Parallel concerns to e-cigs? *Addiction, 110*, 1699–1704. <http://dx.doi.org/10.1111/add.13036>
- Center for Public Health Systems Science. (2016). *Point-of-sale report to the nation: Realizing the power of states and communities to change the tobacco retail and policy landscape*. St. Louis, MO: Center for Public Health Systems Science at the Brown School at Washington University in St. Louis and the National Cancer Institute.
- Centers for Disease Control and Prevention. (2017). *Behavioral risk factor data: Tobacco use (2011 to present) survey data*. Retrieved from <https://chronicdata.cdc.gov/Survey-Data/Behavioral-Risk-Factor-Data-Tobacco-Use-2011-to-pr/wsas-xwh5>
- Cohn, A., Villanti, A., Richardson, A., Rath, J. M., Williams, V., Stanton, C., & Mermelstein, R. (2015). The association between alcohol, marijuana use, and new and emerging tobacco products in a young adult population. *Addictive Behaviors, 48*, 79–88. <http://dx.doi.org/10.1016/j.addbeh.2015.02.005>
- Coleman, B., Johnson, S. E., Alexander, J. P., & Williams, P. (2018). An e-cigarette by many other names: How users describe and categorize ENDS. *Tobacco Regulatory Science, 4*, 61–70. <http://dx.doi.org/10.18001/TRS.4.56>
- Cranford, J. A., Bohnert, K. M., Perron, B. E., Bourque, C., & Ilgen, M. (2016). Prevalence and correlates of “vaping” as a route of cannabis administration in medical cannabis patients. *Drug and Alcohol Dependence, 169*, 41–47. <http://dx.doi.org/10.1016/j.drugalcdep.2016.10.008>
- Cullen, K. A., Ambrose, B. K., Gentzke, A. S., Apelberg, B. J., Jamal, A., & King, B. A. (2018). Notes from the field: Use of electronic cigarettes and any tobacco product among middle and high school students — United States, 2011–2018. *MMWR: Surveillance Summaries, 67*, 1276–1277. <http://dx.doi.org/10.15585/mmwr.mm6745a5>
- Dai, H., & Hao, J. (2017). Geographic density and proximity of vape shops to colleges in the USA. *Tobacco Control, 26*, 379–385. <http://dx.doi.org/10.1136/tobaccocontrol-2016-052957>
- D’Amico, E. J., Tucker, J. S., Miles, J. N., Ewing, B. A., Shih, R. A., & Pedersen, E. R. (2016). Alcohol and marijuana use trajectories in a diverse longitudinal sample of adolescents: Examining use patterns from age 11 to 17 years. *Addiction, 111*, 1825–1835. <http://dx.doi.org/10.1111/add.13442>
- D’Amico, E. J., Tucker, J. S., Miles, J. N., Zhou, A. J., Shih, R. A., & Green, H. D., Jr. (2012). Preventing alcohol use with a voluntary after-school program for middle school students: Results from a cluster randomized controlled trial of CHOICE. *Prevention Science, 13*, 415–425. <http://dx.doi.org/10.1007/s11121-011-0269-7>
- D’Amico, E. J., Tucker, J. S., Pedersen, E. R., & Shih, R. A. (2017). Understanding rates of marijuana use and consequences among adolescents in a changing legal landscape. *Current Addiction Reports, 4*, 343–349. <http://dx.doi.org/10.1007/s40429-017-0170-y>
- DeWalt, D. A., Thissen, D., Stucky, B. D., Langer, M. M., Morgan Dewitt, E., Irwin, D. E., . . . Varni, J. W. (2013). PROMIS Pediatric Peer Relationships Scale: Development of a peer relationships item bank as

- part of social health measurement. *Health Psychology*, 32, 1093–1103. <http://dx.doi.org/10.1037/a0032670>
- DeWitt, E. M., Stucky, B. D., Thissen, D., Irwin, D. E., Langer, M., Varni, J. W., . . . DeWalt, D. A. (2011). Construction of the eight item PROMIS pediatric physical function scales: Built using item response theory. *Journal of Clinical Epidemiology*, 64, 794–804. <http://dx.doi.org/10.1016/j.jclinepi.2010.10.012>
- Ellickson, P. L., D'Amico, E. J., Collins, R. L., & Klein, D. J. (2005). Marijuana use and later problems: When frequency of recent use explains age of initiation effects (and when it does not). *Substance Use & Misuse*, 40, 343–359. <http://dx.doi.org/10.1081/JA-200049356>
- Foulds, J., Veldheer, S., Yingst, J., Hrabovsky, S., Wilson, S. J., Nichols, T. T., & Eissenberg, T. (2015). Development of a questionnaire for assessing dependence on electronic cigarettes among a large sample of ex-smoking E-cigarette users. *Nicotine & Tobacco Research*, 17, 186–192. <http://dx.doi.org/10.1093/ntr/ntu204>
- Frohe, T., Leeman, R. F., Patock-Peckham, J., Ecker, A., Kraus, S., & Foster, D. W. (2017). Correlates of cannabis vape-pen use and knowledge among U.S. college students. *Addictive Behaviors Reports*, 7, 32–39. <http://dx.doi.org/10.1016/j.abrep.2017.11.004>
- Georgiades, K., & Boyle, M. H. (2007). Adolescent tobacco and cannabis use: Young adult outcomes from the Ontario Child Health Study. *Journal of Child Psychology and Psychiatry, and Allied Disciplines*, 48, 724–731. <http://dx.doi.org/10.1111/j.1469-7610.2007.01740.x>
- Giroud, C., de Cesare, M., Berthet, A., Varlet, V., Concha-Lozano, N., & Favrat, B. (2015). E-cigarettes: A review of new trends in cannabis use. *International Journal of Environmental Research and Public Health*, 12, 9988–10008. <http://dx.doi.org/10.3390/ijerph120809988>
- Groskopf, C. (February 10, 2016). *Business in the cloud: What Yelp data reveal about the sudden rise of vape shops in America*. Retrieved from <https://qz.com/608469/what-yelp-data-tells-us-about-vaping/>
- Hasin, D. S., Kerridge, B. T., Saha, T. D., Huang, B., Pickering, R., Smith, S. M., . . . Grant, B. F. (2016). Prevalence and correlates of DSM-5 cannabis use disorder, 2012–2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. *The American Journal of Psychiatry*, 173, 588–599. <http://dx.doi.org/10.1176/appi.ajp.2015.15070907>
- Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., . . . Grant, B. F. (2015). Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. *Journal of the American Medical Association Psychiatry*, 72, 1235–1242. <http://dx.doi.org/10.1001/jamapsychiatry.2015.1858>
- Hernández-Serrano, O., Gras, M. E., & Font-Mayolas, S. (2018). Concurrent and simultaneous use of cannabis and tobacco and its relationship with academic achievement amongst university students. *Behavioral Sciences*, 8, 31. <http://dx.doi.org/10.3390/bs8030031>
- Jones, C. B., Hill, M. L., Pardini, D. A., & Meier, M. H. (2016). Prevalence and correlates of vaping cannabis in a sample of young adults. *Psychology of Addictive Behaviors*, 30, 915–921. <http://dx.doi.org/10.1037/adb0000217>
- Kilmer, B., Caulkins, J., Midgette, G., Dahlkemper, L., MacCoun, R., & Pacula, R. L. (2013). *Before the grand opening: Measuring Washington State's marijuana market in the last year before legalized commercial sales*. Santa Monica, CA: RAND Corporation. Retrieved from [https://www.rand.org/pubs/research\\_reports/RR466.html](https://www.rand.org/pubs/research_reports/RR466.html)
- Kroenke, K., Spitzer, R. L., & Williams, J. B. (2002). The PHQ-15: Validity of a new measure for evaluating the severity of somatic symptoms. *Psychosomatic Medicine*, 64, 258–266. <http://dx.doi.org/10.1097/00006842-200203000-00008>
- Kroenke, K., Strine, T. W., Spitzer, R. L., Williams, J. B. W., Berry, J. T., & Mokdad, A. H. (2009). The PHQ-8 as a measure of current depression in the general population. *Journal of Affective Disorders*, 114, 163–173. <http://dx.doi.org/10.1016/j.jad.2008.06.026>
- Lai, S., Lai, H., Page, J. B., & McCoy, C. B. (2000). The association between cigarette smoking and drug abuse in the United States. *Journal of Addictive Diseases*, 19, 11–24. [http://dx.doi.org/10.1300/J069v19n04\\_02](http://dx.doi.org/10.1300/J069v19n04_02)
- Lauterstein, D., Hoshino, R., Gordon, T., Watkins, B.-X., Weitzman, M., & Zelikoff, J. (2014). The changing face of tobacco use among United States youth. *Current Drug Abuse Reviews*, 7, 29–43. <http://dx.doi.org/10.2174/1874473707666141015220110>
- Masters, M. N., Haardörfer, R., Windle, M., & Berg, C. (2018). Psychosocial and cessation-related differences between tobacco-marijuana co-users and single product users in a college student population. *Addictive Behaviors*, 77, 21–27. <http://dx.doi.org/10.1016/j.addbeh.2017.09.007>
- Meier, E., & Hatsukami, D. K. (2016). A review of the additive health risk of cannabis and tobacco co-use. *Drug and Alcohol Dependence*, 166, 6–12. <http://dx.doi.org/10.1016/j.drugalcdep.2016.07.013>
- Moore, B. A., & Budney, A. J. (2001). Tobacco smoking in marijuana-dependent outpatients. *Journal of Substance Abuse*, 13, 583–596. [http://dx.doi.org/10.1016/S0899-3289\(01\)00093-1](http://dx.doi.org/10.1016/S0899-3289(01)00093-1)
- Morean, M. E., Kong, G., Camenga, D. R., Cavallo, D. A., & Krishnan-Sarin, S. (2015). High school students' use of electronic cigarettes to vaporize cannabis. *Pediatrics*, 136, 611–616. <http://dx.doi.org/10.1542/peds.2015-1727>
- National Academies of Sciences, E., & Medicine. (2018). *Public health consequences of e-cigarettes*. Washington, DC: The National Academies Press.
- National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health. (2014). *The health consequences of smoking—50 years of progress: A report of the Surgeon General*. Atlanta, GA: Centers for Disease Control and Prevention.
- National Institute on Alcohol Abuse and Alcoholism. (2003). *Methodological issues in measuring alcohol use*. Retrieved from <https://pubs.niaaa.nih.gov/publications/arh27-1/18-29.htm>
- Osilla, K. C., Pedersen, E. R., Ewing, B. A., Miles, J. N., Ramchand, R., & D'Amico, E. J. (2014). The effects of purchasing alcohol and marijuana among adolescents at-risk for future substance use. *Substance Abuse Treatment, Prevention, and Policy*, 9, 38. <http://dx.doi.org/10.1186/1747-597X-9-38>
- Peters, E. N., Budney, A. J., & Carroll, K. M. (2012). Clinical correlates of co-occurring cannabis and tobacco use: A systematic review. *Addiction*, 107, 1404–1417. <http://dx.doi.org/10.1111/j.1360-0443.2012.03843.x>
- Pisinger, C., & Døssing, M. (2014). A systematic review of health effects of electronic cigarettes. *Preventive Medicine*, 69, 248–260. <http://dx.doi.org/10.1016/j.ypmed.2014.10.009>
- Prieur, N. (2018). *National adolescent drug trends in 2018: Monitoring the Future press release*. Ann Arbor: University of Michigan, Institute for Social Research. Retrieved from <http://www.monitoringthefuture.org/pressreleases/18drugpr.pdf>
- Rabin, R. A., & George, T. P. (2015). A review of co-morbid tobacco and cannabis use disorders: Possible mechanisms to explain high rates of co-use. *The American Journal on Addictions*, 24, 105–116. <http://dx.doi.org/10.1111/ajad.12186>
- Ramo, D. E., Delucchi, K. L., Hall, S. M., Liu, H., & Prochaska, J. J. (2013). Marijuana and tobacco co-use in young adults: Patterns and thoughts about use. *Journal of Studies on Alcohol and Drugs*, 74, 301–310. <http://dx.doi.org/10.15288/jsad.2013.74.301>
- Ramo, D. E., Liu, H., & Prochaska, J. J. (2012). Tobacco and marijuana use among adolescents and young adults: A systematic review of their co-use. *Clinical Psychology Review*, 32, 105–121. <http://dx.doi.org/10.1016/j.cpr.2011.12.002>
- Ream, G. L., Benoit, E., Johnson, B. D., & Dunlap, E. (2008). Smoking tobacco along with marijuana increases symptoms of cannabis dependence. *Drug and Alcohol Dependence*, 95, 199–208. <http://dx.doi.org/10.1016/j.drugalcdep.2008.01.011>

- Russell, C., Rueda, S., Room, R., Tyndall, M., & Fischer, B. (2018). Routes of administration for cannabis use - basic prevalence and related health outcomes: A scoping review and synthesis. *International Journal on Drug Policy*, *52*, 87–96. <http://dx.doi.org/10.1016/j.drugpo.2017.11.008>
- Saddleson, M. L., Kozlowski, L. T., Giovino, G. A., Hawk, L. W., Murphy, J. M., MacLean, M. G., . . . Mahoney, M. C. (2015). Risky behaviors, e-cigarette use and susceptibility of use among college students. *Drug and Alcohol Dependence*, *149*, 25–30. <http://dx.doi.org/10.1016/j.drugalcdep.2015.01.001>
- Schauer, G. L., Berg, C. J., Kegler, M. C., Donovan, D. M., & Windle, M. (2015). Assessing the overlap between tobacco and marijuana: Trends in patterns of co-use of tobacco and marijuana in adults from 2003–2012. *Addictive Behaviors*, *49*, 26–32. <http://dx.doi.org/10.1016/j.addbeh.2015.05.012>
- Schauer, G. L., Rosenberry, Z. R., & Peters, E. N. (2017). Marijuana and tobacco co-administration in blunts, spliffs, and mulled cigarettes: A systematic literature review. *Addictive Behaviors*, *64*, 200–211. <http://dx.doi.org/10.1016/j.addbeh.2016.09.001>
- Schlienz, N. J., & Lee, D. C. (2018). Co-use of cannabis, tobacco, and alcohol during adolescence: Policy and regulatory implications. *International Review of Psychiatry*, *30*, 226–237. <http://dx.doi.org/10.1080/09540261.2018.1465399>
- Simons, J. S., Dvorak, R. D., Merrill, J. E., & Read, J. P. (2012). Dimensions and severity of marijuana consequences: Development and validation of the Marijuana Consequences Questionnaire (MACQ). *Addictive Behaviors*, *37*, 613–621. <http://dx.doi.org/10.1016/j.addbeh.2012.01.008>
- Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. *Archives of Internal Medicine*, *166*, 1092–1097. <http://dx.doi.org/10.1001/archinte.166.10.1092>
- Substance Abuse and Mental Health Services Administration. (2017). *Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health* (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from <https://www.samhsa.gov/data/>
- Suris, J.-C., Akre, C., Berchtold, A., Jeannin, A., & Michaud, P.-A. (2007). Some go without a cigarette: Characteristics of cannabis users who have never smoked tobacco. *Archives of Pediatrics & Adolescent Medicine*, *161*, 1042–1047. <http://dx.doi.org/10.1001/archpedi.161.11.1042>
- Timberlake, D. S., Haberstick, B. C., Hopfer, C. J., Bricker, J., Sakai, J. T., Lessem, J. M., & Hewitt, J. K. (2007). Progression from marijuana use to daily smoking and nicotine dependence in a national sample of U.S. adolescents. *Drug and Alcohol Dependence*, *88*, 272–281. <http://dx.doi.org/10.1016/j.drugalcdep.2006.11.005>
- Tucker, J. S., Orlando, M., & Ellickson, P. L. (2003). Patterns and correlates of binge drinking trajectories from early adolescence to young adulthood. *Health Psychology*, *22*, 79–87. <http://dx.doi.org/10.1037/0278-6133.22.1.79>
- Tullis, L. M., Dupont, R., Frost-Pineda, K., & Gold, M. S. (2003). Marijuana and tobacco: A major connection? *Journal of Addictive Diseases*, *22*, 51–62. [http://dx.doi.org/10.1300/J069v22n03\\_05](http://dx.doi.org/10.1300/J069v22n03_05)
- U.S. Department of Health and Human Services. (2016). *E-cigarette use among youth and young adults. A report of the Surgeon General*. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
- Winstock, A., Barratt, M., Ferris, J., & Maier, L. (2017). *Global Drug Survey, 2017: Global overview and highlights*. Retrieved from [https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2017\\_key-findings-report\\_final.pdf](https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2017_key-findings-report_final.pdf)

Received October 17, 2018

Revision received February 25, 2019

Accepted February 28, 2019 ■